These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2339367)

  • 1. Antithrombin-III assay without influence of heparin cofactor II.
    Enomoto M; Tanimizu I; Sakuragawa N
    Thromb Res; 1990 Mar; 57(5):729-36. PubMed ID: 2339367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
    Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin activity of a fucan sulfate from the brown seaweed Ecklonia kurome.
    Nishino T; Aizu Y; Nagumo T
    Thromb Res; 1991 Jun; 62(6):765-73. PubMed ID: 1926066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
    Shimotori T; Sakuragawa N
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of interference by heparin cofactor II in the DuPont aca antithrombin-III assay.
    Hortin GL; Tollefsen DM; Santoro SA
    Am J Clin Pathol; 1988 Apr; 89(4):515-7. PubMed ID: 3354504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
    Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
    Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and biological property of heparin cofactor II: activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans.
    Yamagishi R; Niwa M; Kondo S; Sakuragawa N; Koide T
    Thromb Res; 1984 Dec; 36(6):633-42. PubMed ID: 6084876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082.
    Ofosu FA; Fareed J; Smith LM; Anvari N; Hoppensteadt D; Blajchman MA
    Eur J Biochem; 1992 Jan; 203(1-2):121-5. PubMed ID: 1730217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of heparin cofactor II on the antithrombin III activities measured by thrombin methods or factor Xa methods--fundamental studies and clinical studies using the plasma of pregnant women].
    Akai Y; Shiga S; Tohyama K; Shimatsu A; Ichiyama S
    Rinsho Byori; 2000 Sep; 48(9):867-71. PubMed ID: 11051806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin cofactor II deficiency in the elderly: comparison with antithrombin III.
    Kario K; Matsuo T; Kobayashi H
    Thromb Res; 1992 Jun; 66(5):489-98. PubMed ID: 1381849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
    Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
    Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans.
    Carson L; Doctor VM
    Thromb Res; 1990 May; 58(4):367-81. PubMed ID: 1972302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin cofactor II: experimental approach to a new assay and clinical results.
    Vinazzer H; Stocker K
    Thromb Res; 1991 Feb; 61(3):235-41. PubMed ID: 2028443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive chromogenic anti-factor Xa assay and its use in the classification of antithrombin deficiencies.
    Kovács B; Bereczky Z; Selmeczi A; Gindele R; Oláh Z; Kerényi A; Boda Z; Muszbek L
    Clin Chem Lab Med; 2014 Dec; 52(12):1797-806. PubMed ID: 24968404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifactor Xa activity measured with amidolytic methods.
    Odegård OR; Lie M; Abildgaard U
    Haemostasis; 1976; 5(5):265-75. PubMed ID: 1017722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity.
    Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin cofactor II assay. Elimination of heparin and antithrombin-III effects.
    Nakhleh R; Vogt JM; Edson JR
    Am J Clin Pathol; 1988 Mar; 89(3):353-8. PubMed ID: 3348170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity.
    de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA
    Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III.
    Koyama T; Parkinson JF; Sié P; Bang NU; Müller-Berghaus G; Preissner KT
    Eur J Biochem; 1991 Jun; 198(3):563-70. PubMed ID: 1646716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.